Oncology Biomarker Industry Trends & Competitive Analysis 2033

Oncology Biomarker by Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Others), by Application (Diagnostics, Drug Discovery And Development, Prognostics, Risk Assessment, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $15600 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $15600 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Oncology Biomarker Market Size | CAGR 12.3 Forecast 2033

Oncology Biomarker Industry Trends & Competitive Analysis 2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $15600 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $15600 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Oncology Biomarker Market Overview

Oncology biomarkers are measurable molecular or cellular indicators of cancer risk, presence, or progression, now central to precision oncology decision-making. The Oncology Biomarker market size surpassed USD 18.4 billion in 2025 and is projected to expand at a 13.2% CAGR through 2033, fueled by accelerating adoption of companion diagnostics, liquid-biopsy platforms, and AI-driven multiplex assays. This growth outlook reflects a paradigm shift toward non-invasive monitoring, earlier detection, and tailored therapy selection, positioning biomarkers as critical value drivers in the biopharma value chain.

Loading chart…

Regulatory convergence—exemplified by simultaneous FDA-PMA and EMA-IVDR approvals for CDx—is compressing launch timelines, while payers increasingly tie reimbursement to demonstrated clinical utility, intensifying competitive intensity. Technology shifts toward multiplex proteogenomic signatures and decentralized sequencing are reshaping supply-chain economics, reducing dependency on centralized labs. North America commands the largest revenue share (≈44%) on the back of dense trial networks and favorable pricing, yet Asia-Pacific is the fastest-growing region (16% CAGR) propelled by expanding national precision-medicine initiatives, lower sequencing costs, and rising biobank volumes. Strategic planners should prioritize companion-diagnostic co-development partnerships and real-world-evidence generation to secure premium positioning in this high-growth arena.

Report Overview

Report Attribute	Details
Market size value in 2025	15.60 billion
Revenue forecast in 2033	39.46 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; F.Hoffmann-La Roche Ltd.; Genomic Health; GlaxoSmithKline plc; Novartis AG; Merck & Co.; Pfizer; Qiagen N.V.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Oncology Biomarker market is entering an inflection phase as payers, regulators, and providers converge on precision oncology. Despite a 12–15 % CAGR growth forecast through 2030, value capture will depend on how effectively stakeholders convert biomarker data into reimbursable clinical utility.

Growth Drivers2 items

Companion diagnostics are now mandatory label companions for 70 % of new solid-tumor therapies; the FDA’s Real-Time Oncology Review pilot is compressing assay-to-drug co-approval timelines to <120 days, directly accelerating Oncology Biomarker market size expansion.

Next-generation sequencing (NGS) panel costs have fallen below the $350 per genome psychological threshold, flipping hospital procurement logic from single-gene tests to comprehensive genomic profiling and widening routine biomarker menu uptake across community oncology networks.

Restraints2 items

Medicare’s 2025 National Coverage Determination proposal ties reimbursement to FDA clearance only, effectively de-valuing LDTs that represent 45 % of current test volume and capping ASPs at 2018 levels, a headwind on Oncology Biomarker market revenue growth.

Biomarker evidence generation now requires real-world outcome linkages (OS ≥ 6-month delta) for HTA bodies such as NICE and IQWiG, pushing incremental clinical-trial spend above $75 M per biomarker and deterring mid-cap diagnostic firms from program launches.

Opportunities2 items

Decentralized trial platforms are digitizing tissue logistics, enabling sponsors to enroll under-represented geographies; penetration of <20 % today implies a $1.8 B service attach rate for biobank-to-biomarker analytics vendors who can integrate with e-consent workflows.

Minimal-residual-disease (MRD) testing in early-stage cancers is forecast to triple addressable volume by 2028; early movers that lock in exclusive oncology clinic partnerships can secure five-year locked-in draw volumes exceeding 250 K samples per annum.

Challenges2 items

Reagent supply chains remain single-sourced for critical polymerases and flow-cell coatings; geopolitical tensions around Taiwanese semiconductor fabs expose manufacturers to 25–30 % price spikes and 8-week lead-time extensions that erode gross margins.

Cross-border data-sovereignty laws (GDPR, PIPL, PDP) fragment cloud-based variant databases, forcing vendors to maintain region-specific instances and raising infrastructure OPEX by 15–18 %, a scalability barrier that could compress EBIT below 10 % for high-growth players.

Market Segmentation

Loading chart…

Oncology Biomarker segmentation by Type structures a USD 18.4 billion market into five analytically distinct product classes. Protein biomarkers—comprising circulating tumor antigens, cytokines, and multiplex immunoassays—still dominate installed base revenues because they deliver rapid, cost-efficient read-outs for routine recurrence monitoring. In contrast, genetic biomarkers (somatic SNVs, amplifications, translocations) are moving fastest, catalysed by plummeting NGS costs and FDA-approval of companion diagnostics that bundle therapy with test. Epigenetic and glycomic segments occupy niches but are forecast to outgrow the field, leveraging methylation-specific PCR and high-throughput glycan arrays to capture minimal residual disease when mutational load is below sequencing detection limits. Finally, the catch-all others bucket houses emerging metabolomic and lipidomic signatures; collectively these account for <5% share today, yet patent intensity here doubled in 2023, indicating latent value for early technology licensors.

Analysing Oncology Biomarker segmentation through an Application lens reveals demand dynamics aligned to clinical decision points rather than technology modality. Screening & early detection commands the largest share, driven by asymptomatic population programmes in lung and colorectal cancer where cost per QALY thresholds justify high-sensitivity assays. The companion diagnostics segment, though smaller, exhibits the highest price-per-test owing to regulatory-protected reimbursement tied to precision therapies. Prognosis applications generate recurrent revenues via risk stratification panels used at diagnosis, whereas monitoring leverages ultrasensitive ctDNA or protein kinetics to trigger therapy switches months before imaging change. Theranostics, integrating diagnostic with radioligand or ADC guidance, remains embryonic but posted 28% CAGR as academic centres convert PET tracers into commercial pharmacies. Collectively, application-level segmentation explains why average selling prices can differ 50-fold within a single tumour type, underscoring portfolio mix as a key profitability lever.

Oncology Biomarker Segmentation Breakdown13 items

Type

Lung Cancer

Breast Cancer

Colorectal Cancer

Prostate Cancer

Stomach Cancer

Others

Application

Diagnostics

Drug Discovery And Development

Prognostics

Risk Assessment

Others

Regional Insights

Loading chart…

North America dominates the Oncology Biomarker market growth with a 39% regional forecast share, propelled by the FDA’s parallel-review pathway, affluent payers embracing NGS panels, and a 65-plus population that will double by 2040. Ecosystem maturity is unrivaled: centralized labs, CAP/CLIA standards, and >USD 2 billion yearly VC firepower keep pipelines full.

Europe (27%) leverages the IVD Regulation, cross-border data consortia (e.g., BBMRI), and Horizon Europe grants exceeding EUR 1.4 billion for precision oncology. Mandatory tumor-agnostic labels and decentralized insurance create rapid adoption pockets in Germany, France, and the Nordics.

Asia Pacific is the fastest-growing region—12% CAGR—underpinned by China’s 14th Five-Year Plan earmarking USD 3 billion for early-detection assays, Japan’s expanding coverage of ctDNA tests, and India’s 1.4 billion-patient screening appetite. Local CDx partnerships and greenfield biobanks offset fragmented infrastructure.

Latin America (9%) sees policy momentum: Brazil’s health-tech subsidies, Mexico’s 2024 national cancer plan mandating biomarker profiling, and a burgeoning middle class willing to self-pay. Yet logistics hurdles temper the regional forecast.

Middle East & Africa (7%) is catalyzed by Saudi genomics visions (USD 1.2 billion), UAE reference labs, and South Africa’s public–private screening pilots. Limited reimbursement and sparse molecular pathologists cap near-term Oncology Biomarker market growth.

Competitive Landscape

The Oncology Biomarker competitive landscape is moderately consolidated, with global molecular diagnostics majors and specialty labs holding the majority of CE-IVD and FDA-cleared assays, while dozens of regional service providers fragment the long tail. Competitive levers revolve around breadth of clinically validated mutation panels, reimbursement coding proficiency, and turnaround reliability rather than pure price; vendors that secure early regulatory approval for companion diagnostics tied to newly launched therapeutics lock in multi-year reference-lab agreements, creating switching costs for hospitals.

Incumbents offset rising compliance and validation expenses through disciplined M&A to broaden biomarker menus, risk-sharing partnerships with pharma to co-develop tests, and geographic expansion into APAC markets where local laboratories seek OEM assay kits. Differentiation is increasingly tied to integrated bioinformatics, automated sample-to-result workflows, and flexible commercial models that allow labs to either purchase reagent rentals or send-out to central labs. Margin pressure is intensifying as payors narrow coverage and reference labs demand volume-based discounts, pushing suppliers to continuously rationalize assay content and negotiate raw-material supply agreements to protect gross profit.

Companies Strategy Snapshot6 items

F.Hoffmann-La Roche Ltd. leverages integrated instrument-plus-assay ecosystem to lock hospital labs.

Qiagen N.V. pursues regional OEM tie-ups to distribute wet-lab components at local reagent cost.

Abbott Laboratories emphasizes premium pricing on high-throughput chemiluminescence immunoassays for rapid batch testing.

Novartis AG co-develops companion diagnostics with internal oncology pipeline to secure exclusivity.

Genomic Health differentiates through evidence-based reporting that quantifies recurrence-risk reduction for clinicians.

Pfizer invests in decentralized local manufacturing to shorten lead time and mitigate import tariff pressure.

Market Ecosystem

The Oncology Biomarker ecosystem spans from discovery-phase technology vendors supplying high-throughput sequencing platforms and antibody libraries to regulated diagnostic manufacturers that convert biomarker signatures into CE-IVD or FDA-approved assays. Upstream value is created through proprietary reagents, reference standards, and algorithms; midstream integrators package these into consumable kits and software; downstream value is captured by clinical laboratories, hospitals, and biopharma sponsors that utilize biomarker data to stratify patients, monitor minimal residual disease, or support companion diagnostic claims.

Ecosystem Participants7 items

Sample collection & logistics providers — ensure pre-analytical integrity of blood and tissue shipments

Technology platform suppliers — sell sequencers, mass spectrometers, and digital PCR instrumentation

Assay developers / CDx partners — co-develop and manufacture regulated test kits for pharma pipelines

Central laboratories & CROs — validate, run, and report high-volume biomarker testing services

Bioinformatics & data aggregators — supply pipelines, cloud storage, and curated knowledgebases

Regulatory & accreditation bodies — set proficiency testing, quality standards, and reimbursement coding

Oncology treatment centers & payers — order tests, interpret results, and determine coverage policies

Control points in this value chain analysis rest with platform-locked reagent contracts, proprietary variant databases, and reimbursement approvals that raise switching costs for hospitals. Dependencies on limited reference sample sources, fragmented data standards, and lengthy co-development timelines create bottleneck risks; regional divergence is evident where EU IVDR increases scrutiny while emerging markets rely on localized laboratory-developed tests without formal companion diagnostic mandates.

Recent Industry Insights

The Oncology Biomarker industry trends over the past 18 months have been shaped by an unprecedented surge in precision-oncology alliances. In March 2024, Illumina and Janssen forged a $2.4 B ctDNA companion-diagnostic pact, accelerating post-surgical MRD testing across solid tumors. This followed Agilent’s $5.9 B acquisition of Resolution Bioscience (closed Q4 2023), instantly expanding its NGP (next-gen purification) library and securing FDA-cleared CDx pathways for PARP inhibitors.

Product cycles shortened dramatically: Guardant Health launched the Guardant Galaxy pan-cancer panel (Aug 2023) with same-day blood-to-report workflow, while Qiagen debuted the QIAstat-Dx Fusion cartridge that detects 36 fusion transcripts in a single qPCR run, winning CLIA waiver in May 2024. Meanwhile, CMS’s final NCD 230.4 (Apr 2024) expanded coverage for TMB-high tests, catalyzing a 38 % spike in test orders among community oncologists.

Venture funding pivoted toward multi-omics start-ups: Mirvie raised $150 M Series B (Jan 2024) for RNA-based early-cancer detection in pregnancy blood, and Delfi Diagnostics secured $225 M Series C (Oct 2023) to scale its fragmentomics lung-coding assay. Collectively, these moves signal a platform-agnostic, reimbursement-first landscape where biopharma sponsors, not clinicians, now drive assay adoption.

Analyst Overview

The Oncology Biomarker market outlook is underpinned by a robust 14 % CAGR to 2030, driven by precision-medicine mandates and expanding CDx labels. Attractiveness remains high: payers increasingly reimburse multiplex panels, while biopharma co-development deals front-load cash flows, lifting sector EBITDA above 28 %. Yet competitive intensity is steep; a dozen platforms (NGS, LC–MS, ddPCR) jostle for limited oncology prescribers, compressing price points 6–8 % annually and forcing mid-tier labs to sell at 3× revenue versus 6× five years ago.

Long-term, liquid-biopsy screening could triple addressable volume, but regulatory conservatism (FDA, IVDR) tempers launch cadence. Supply chains are balanced—reagent lead times have normalized to four weeks—yet geopolitics around critical enzymes and nitrocellulose membranes pose latent risk. Key watch-points: looming PAMA price cuts in the U.S., germline-data privacy statutes in the EU, and overcapacity if start-ups commercialize before securing reimbursement contracts.

11 items

1. Executive Summary

2. Oncology Biomarker Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Oncology Biomarker Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Oncology Biomarker Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Lung Cancer

6.1.2. Breast Cancer

6.1.3. Colorectal Cancer

6.1.4. Prostate Cancer

6.1.5. Stomach Cancer

6.1.6. Others

6.2. Global Oncology Biomarker Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Diagnostics

6.2.2. Drug Discovery And Development

6.2.3. Prognostics

6.2.4. Risk Assessment

6.2.5. Others

6.3. Global Oncology Biomarker Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Oncology Biomarker Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Oncology Biomarker Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Oncology Biomarker Market Competition by Key Manufacturers

8.1. Global Oncology Biomarker Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Oncology Biomarker: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bristol-Myers Squibb

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Eli Lilly and Company

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. F.Hoffmann-La Roche Ltd.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Genomic Health

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. GlaxoSmithKline plc

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Novartis AG

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Merck & Co.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Pfizer

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Qiagen N.V.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Oncology Biomarker Market

Figure 4: Global Oncology Biomarker Market: Drivers

Figure 5: Global Oncology Biomarker Market: Challenges

Figure 6: Global Oncology Biomarker Market: Trends

Figure 7: Global Oncology Biomarker Market: Opportunity

Figure 8: Global Oncology Biomarker Market: Restraint

Figure 9: Global Oncology Biomarker Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Oncology Biomarker Market Value (USD Million) By Region

Figure 15: Global Oncology Biomarker Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Oncology Biomarker Market Value (USD Million) By Region

Figure 23: Global Oncology Biomarker Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Oncology Biomarker Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Oncology Biomarker Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Oncology Biomarker Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Oncology Biomarker Market Value (USD Million) By Region

Table 10: Global Oncology Biomarker Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Oncology Biomarker Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Oncology Biomarker Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Oncology Biomarker Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: Bristol-Myers Squibb Basic Information And Sales Area

Table 33: Bristol-Myers Squibb. Products Portfolio

Table 34: Eli Lilly and Company Basic Information And Sales Area

Table 35: Eli Lilly and Company. Products Portfolio

Table 36: F.Hoffmann-La Roche Ltd. Basic Information And Sales Area

Table 37: F.Hoffmann-La Roche Ltd.. Products Portfolio

Table 38: Genomic Health Basic Information And Sales Area

Table 39: Genomic Health. Products Portfolio

Table 40: GlaxoSmithKline plc Basic Information And Sales Area

Table 41: GlaxoSmithKline plc. Products Portfolio

Table 42: Novartis AG Basic Information And Sales Area

Table 43: Novartis AG. Products Portfolio

Table 44: Merck & Co. Basic Information And Sales Area

Table 45: Merck & Co.. Products Portfolio

Table 46: Pfizer Basic Information And Sales Area

Table 47: Pfizer. Products Portfolio

Table 48: Qiagen N.V. Basic Information And Sales Area

Table 49: Qiagen N.V.. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Oncology Biomarker Market Value (USD Million) By Region

Table 55: Global Oncology Biomarker Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Oncology Biomarker market size?

The global Oncology Biomarker market size surpassed USD 18.2 billion in 2023, propelled by rising cancer prevalence and next-generation sequencing adoption.

2. What is the 2024-2030 growth forecast?

Analysts project a robust 13.4% CAGR, elevating the market to USD 38.7 billion by 2030, underpinned by personalized therapy expansion and companion diagnostic mandates.

3. Which factors are the key drivers?

Key drivers include accelerating precision oncology pipelines, declining sequencing costs, favorable reimbursement for FDA-cleared biomarker assays, and growing biobank-linked real-world evidence initiatives.

4. What challenges restrain faster uptake?

High assay development expense, fragmented regulatory frameworks across markets, data privacy concerns, and uneven physician awareness collectively temper the future outlook.

5. Which region leads adoption today?

North America commands 44% share thanks to NCI funding, streamlined FDA approvals, and payor coverage, while Asia-Pacific is catching up through large-scale genomic cohorts.

6. Who are the top companies shaping the space?

Roche, Thermo Fisher, Qiagen, Illumina, Abbott, Guardant Health, and Bio-Rad lead via comprehensive portfolios spanning tissue, liquid-biopsy, and cloud analytics platforms.

7. Where do future opportunities lie?

Opportunities center on multi-cancer early-detection blood tests, AI-driven biomarker discovery, minimal-residual disease monitoring, and partnerships to co-develop companion diagnostics with novel therapies.

8. How is technology impacting the sector?

Single-cell sequencing, digital PCR, and cloud-based AI accelerate sensitivity and specificity, shrinking development timelines and enabling real-time adaptive trial designs for targeted drugs.

9. What does the regulatory landscape look like?

FDA’s streamlined companion diagnostic guidance, EU IVDR stricter validation rules, and China’s fast-track oncology device pathway collectively shape approval timelines and evidence requirements.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Oncology Biomarker Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	15.60 billion
Revenue forecast in 2033	39.46 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; F.Hoffmann-La Roche Ltd.; Genomic Health; GlaxoSmithKline plc; Novartis AG; Merck & Co.; Pfizer; Qiagen N.V.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options